LY2228820

p38 MAP kinase (MAPK) inhibitor

LY2228820

p38 MAP kinase (MAPK) inhibitor

From: 47 USD
Catalog #
(Select a product)
p38 MAP kinase (MAPK) inhibitor
Add to Wish List

Overview

LY2228820 is a trisubstituted imidazole derivative and a potent inhibitor of the α- and β-isoforms of p38 MAP kinase (MAPK) in vitro (IC₅₀ = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities (Campbell et al.). This product is supplied as the dimesylate salt of the molecule.


MAINTENANCE AND SELF-RENEWAL
· Combined with other small molecule inhibitors such as Rapamycin (Catalog #73362) and SR1 (Catalog #72342; Li et al.) or SB203580 (Catalog #72222), Vx702, and BIRB-796 (Catalog #72682), enhances the self-renewal of cord blood-derived hematopoietic stem cells (Baudet et al.).

CANCER RESEARCH
· By inhibiting p38 MAPK, which is highly expressed in human cancers, LY2228820 is potent and selective at inhibiting tumor growth in animal models of a variety of human cancers (Campbell et al.).
Cell Type
Cancer Cells and Cell Lines, Hematopoietic Stem and Progenitor Cells
Species
Human, Mouse, Non-Human Primate, Other, Rat
Application
Maintenance
Area of Interest
Cancer, Stem Cell Biology
CAS Number
862507-23-1
Chemical Formula
C₂₄H₂₉FN₆ • 2CH₃SO₃H
Purity
≥ 98%
Pathway
p38 MAPK
Target
p38 MAPK

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
74162, 74164
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
74162, 74164
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.